Section Arrow
Quote
KPTI.NASDAQ
- Karyopharm Therapeutics Inc.
Quotes are at least 15-min delayed:2026/02/23 02:26 EST
Regular Hours
Last
 9.67
0 (0.00%)
Day High 
9.815 
Prev. Close
9.67 
1-M High
9.94 
Volume 
312.60K 
Bid
9.4
Ask
9.8
Day Low
9.4 
Open
9.7 
1-M Low
5.875 
Market Cap 
177.39M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.85 
20-SMA 7.23 
50-SMA 7.13 
52-W High 10.38 
52-W Low 3.51 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-14.70/-2.51
Enterprise Value
347.05M
Balance Sheet
Book Value Per Share
-15.97
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
145.24M
Operating Revenue Per Share
7.95
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CDIOCardio Diagnostics Holdings Inc.2.88+0.64+28.57%-- 
IBRXImmunityBio8.7+0.09+1.05%-- 
GERNGeron Corp1.88-0.04-2.08%-- 
QNCXQuince Therapeutics0.1501-0.0121-7.46%-- 
RXRXRecursion Pharmaceuticals3.42-0.3-8.06%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.